Show simple item record

dc.contributor.advisorSatoskar, Abhay
dc.creatorNatarajan, Gayathri
dc.date.accessioned2015-05-01T16:03:08Z
dc.date.available2015-05-01T16:03:08Z
dc.date.issued2015-02
dc.identifier.citationNatarajana, Gayathri, Cesar Terrazasb, Steve Oghumuc, Sanjay Varikutib, Jason A. Dubovskyd, John C. Byrdef and Abhay R. Satoskar. "Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells." OncoImmunology. Accepted author version posted online: 09 Jun 2015. DOI: 10.1080/2162402X.2015.1057385en_US
dc.identifier.urihttp://hdl.handle.net/1811/68873
dc.descriptionBiological Sciences: 2nd Place (The Ohio State University Edward F. Hayes Graduate Research Forum).en_US
dc.descriptionThis is an Accepted Manuscript of an article published by Taylor & Francis Group in OncoImmunology on 06/09/2015, available online: http://www.tandfonline.com/10.1080/2162402X.2015.1057385en_US
dc.description.abstractIbrutinib (PCI-32765) is an irreversible dual Btk/Itk inhibitor shown to be effective in treating several B cell malignancies. However, limited studies have been conducted to study the effect of this drug on myeloid cell function. Hence, we studied the effect of ibrutinib treatment on TLR-4 mediated activation of bone marrow derived dendritic cell culture (DCs). Upon ibrutinib treatment, LPS-treated DCs displayed lower synthesis of TNF-α and nitric oxide and higher induction of IL-6, TGF-β and IL-18. While ibrutinib dampened MHC-II and CD86 expression on DCs, CD80 expression was upregulated. Further, ibrutinib-treated DCs promoted T cell proliferation and enhanced IL-17 production upon co-culture with nylon wool enriched T cells. Taken together, our results indicate that ibrutinib modulates TLR-4 mediated DC activation to promote an IL-17 response. We describe a novel mode of action for ibrutinib on DCs which should be explored to treat other forms of cancer besides B cell malignancies.en_US
dc.language.isoen_USen_US
dc.publisherTaylor & Francis Groupen_US
dc.relation.ispartofseries2015 Edward F. Hayes Graduate Research Forum. 29then_US
dc.subjectIbrutiniben_US
dc.subjectdendritic cellsen_US
dc.subjectTLR-4en_US
dc.subjectT cellsen_US
dc.subjectIL-17en_US
dc.subjectBtken_US
dc.titleIbrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cellsen_US
dc.typeArticleen_US
dc.description.embargoA one-year embargo was granted for this item.en_US
dc.identifier.doi10.1080/2162402X.2015.1057385en_US


Files in this item

Thumbnail

Items in Knowledge Bank are protected by copyright, with all rights reserved, unless otherwise indicated.

This item appears in the following Collection(s)

Show simple item record